Total number of databases listings
From 2011 to 2014 there is a sharp increase in total number of adipose cell-based clinical trials worldwide. It jumped more than 3 times (from 11 in 2011 to 40 in 2014). The number of academic-based trials remained flat in the last 3 years. However, there was a big increase in industry-sponsored trials in 2014:
It is important to recognize that significant part of so-called “industry” trials, listed in databases is not authorized (or sanctioned) by governmental regulatory agencies. These “trials” registered by clinics, which offer these cell therapies commercially. Therefore, the most correct term here is “listings” instead of “trials”. My rough estimation for 2014 is about 35-40% of listings are not authorized (not regulated). Because such clinics are commercial, it falls into “industry” category in my analysis.
Adipose tissue-derived cell types
The next slice of my data is analysis of cell types. I divided it for 2 categories: freshly isolated stromal vascular fraction (SVF) and expanded in culture – adipose stem cells (ASC). Here is a trend:
As you can see, there is a equal interest to both cell types – SVF and ASC over the last 4 years.
This post is a part of series Breaking Down Fat. In this series we will talk about identification, characterization and clinical processing of potentially therapeutic cell populations from adipose tissue. We started this series in response to the growing trend of wide (mostly uncontrolled) clinical use adipose-derived cells and some controversies/ misconceptions in the field.If you would like to contribute to this series or become a sponsor, please contact us!